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tion with treatment in chronic health conditions. However, responsiveness (sensi-
tivity to change) still remained unknown. Thus, the goal of this study in a
prospective cohort of subjects with refractory Neuropathic pain (NeP) was to ex-
plore the ability of SATMED-Q to detect changes in patient=s satisfaction with
therapy. METHODS: We used data from a 6-month cohort prospective study car-
ried-out in pain clinics, which included patients with NeP referred to pain clinics to
change their pain therapy because of its resistance to previous treatments (pain
score in a 0-100 mm VAS above 40 mm after, at least, one course of an analgesic at
standard doses. Sensitivity to change of the SATMED-Q was assessed by mean of
comparing changes in the overall and sub-domains satisfaction scores between
baseline and end-of-trial visits according with patients response criterion; end-of-
trial pain reduction 50% (responder). Also, correlations between baseline to end-
of-trial change in pain intensity and satisfaction scores were computed. RESULTS:
The sample was formed with 755 subjects with refractory NeP; mean age: 57.8
years, 60.6% women, mean pain score of 74.2 (15.1) mm. After changing their ther-
apy, 47% of patients were considered responders, and pain intensity was reduced
by an average 42.9% (32.4), p0.001, which was significantly correlated (r-0.524,
p0.001) with overall treatment satisfaction improvement in SATMED-Q which
varied from 50.3 (17.3) to 74.2 (14.4) pts, p0.001. Pearson r-coefficients between
pain variation and SATMED-Q subdomains changes were significant and ranged
between -0.189 and -0.465 (p0.01 in all cases). Overall sore in SATMED-Q was
significantly higher in responders than in non-responders; 80.9 (79.6-82.3) versus
66.5 (65.0-98.0), respectively, p0.001. CONCLUSIONS: The SATMED-Q demon-
strated to be sensitivity to patient=s satisfaction with treatment change in resistant
NeP patients.
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OBJECTIVES: With fewer products in the development pipeline new technologies
entering the market often rely on demonstrating alternative value offerings. Im-
provements in administration and patient convenience are often desired but our
aim is to discover whether this leads to a tangible pricing and reimbursement
opportunity. METHODS: In-depth analysis was conducted across an array of prod-
ucts in a variety of disease areas where improvements in administration were the
only main differentiating factor. A variety of national and regional payers were
interviewed across European markets to gain an understanding of the value attrib-
uted to these factors. Payer advising key opinion leaders, influential in aiding de-
cision making, were also key to the research as they gave a more clinical perspec-
tive. In addition to value seen through administration, other endpoints such as
quality of life were assessed in terms of offering a potential price premium. Qual-
itative analysis of these findings permitted us to place markets in the framework
and extrapolate key findings to other key markets. RESULTS: With increased scru-
tiny of new medicinal products entering European markets since the economic
uncertainty of the past 2 years, administration advantages only pertain to a mar-
ginal price premium opportunity. Priority, in terms of pricing potential, is predom-
inantly derived from value attributed to a product’s efficacy. CONCLUSIONS:
Stakeholders, while enthusiastic about products offering patient advantages, had a
low willingness to pay for administration improvements. Physicians however were
more positive towards the value they placed on patient convenience and would be
willing to pay for administration and quality of life advances.
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OBJECTIVES: To assess the communication of observational studies of Cardiovas-
cular and Metabolism therapeutic area (CVM) published in 6 Spanish journals in
2009 using the STROBE statement (Strengthening the Reporting of Observational
Studies in Epidemiology). METHODS: It were identified all published observational
studies in Atención Primaria, Gaceta Sanitaria, Hipertensión, Medicina Clínica, Re-
vista Clínica Española y Revista Española de Cardiología related to CVM therapeutic
area. For each paper, three independent reviewers applied the 34 items of the
STROBE statement. RESULTS: Throughout 2009, 74 CVM observational studies
were published in the evaluated journals. The most frequent design was prospec-
tive (43.15%) and cross-sectional (37.5%), and the least retrospective (19.4%). The
study main objective was on pathology (74.3%), followed by drug and non-pharma-
cological interventions (20.3%) and diagnosis (5.4%). The mean of complied items
was 20 on 34 (SD  3.7), with a maximum of 24 (SD  2) in Gaceta Sanitaria and a
minimum of 19 (SD  2.8) in Hipertensión. The Methods and Results sections
showed more deficiencies. CONCLUSIONS: Evaluated papers comply with slightly
more than a half items (58%) of the STROBE recommendations. Increasing STROBE
use could improve the quality of the communication of these studies results, pro-
viding greater transparency for analysis and increasing its usefulness in clinical
practice.
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BACKGROUND: Collecting patients’ data in observational longitudinal studies is
often a concern in terms of data accuracy and patient follow up. Depending of the
study design, the physicians’ assessment might be not sufficient and/or non-fea-
sible. Direct to patient contact (DtPC) process is commonly used to maximize the
long-term follow up and ensure continuity and quality in data collection.
OBJECTIVES: To demonstrate the benefit of DtPC, through example of multina-
tional study. Challenges were to implement feasible and robust methods to collect
and confirm Events of Interest for the study (EoI) in ‘real-life’ settings, fitting health
care standards, regulatory and cultural requirements of countries involved.
METHODS: Longitudinal, international, observational study. Enrolling physicians
were not primary patient’s Health Care Providers; consequently, patients had to be
the main contact to capture the EoI. Patients had to complete and sign a Contact
Order Form that allowed trained interviewers performing follow-up calls at regular
time points during the follow up period. Baseline clinical and demographic data
were collected by enrolling physicians. Then, the medical confirmation of EoI de-
tected through telephone interviews was ensured by the involvement of the con-
cerned EoI’s treating physician. RESULTS: On average 85% successful interviews
were performed, 2% patients withdrawn their consent, 3% patients were lost to
follow up. On average, 80% of the EoI’s treating physicians accepted the process for
medical confirmation and data collection of the EoI, despite strong variations de-
pending on the country.CONCLUSIONS:The results of this study are in accordance
with our previous experiences and confirms the benefits of using DtPC in interna-
tional observational and longitudinal studies. This process enabled a harmonised
and centralised method to obtain real life data overview for all patients included,
whatever their country, a high level of patient adherence and a low rate of patient
withdrawal, despite the large number of countries involved.
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OBJECTIVES: Comorbidities, conditions or diseases besides the one of primary
interest is often measured using a comorbidity index condenses all the coexistent
conditions to a single score. As the use of administrative data is gaining more and
more attention within health economics there is a need for summarising the in-
dexes validity such use. The objective of this study was to review published meth-
ods to measure comorbidity in administrative data. METHODS: A structured
search, using as primary search terms comorbidity, multimorbidity, and coexisting
disease, to find comorbidity indexes validated for use in administrative data anal-
ysis was undertaken in Embase.com to identify studies published since 2000 in
which an index to measure comorbidity was described. For purposes of validation,
correlation coefficients, ratios, explained variance, and the area under the receiver
operating characteristic curve were used. Regression models predicting future
events that were significant or significantly improved after adding comorbidity as
a covariate was considered to support validity. Parameters used to assess reliability
were among others correlation coefficients. RESULTS: Sixtyfour publications were
studied resulting in two different indexes, to measure comorbidity in administra-
tive data were identified. The Charlson Comorbidity Index (CCI) generated the
greatest number of studies on comorbidity assessment in administrative data and
it had the most consistent results regarding validity and reliability. CCI compiles
the weighted mortality association of nineteen different diseases with a number of
adaptations for specific circumstances. CONCLUSIONS: The main finding is that
the CCI remains the most used and validated index for assessment of comorbidity
in administrative data. Assessment of comorbidity is an area of interest for both
health economists and epidemiologists and it seems to be receiving increased
attention.
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OBJECTIVES: Patient Reported Outcomes (PROs) play an important role in evaluat-
ing patient quality of life and comparative efficacy of various treatments. Another
potential use of PROs is for chronic disease management, which can provide useful
data to physicians and patients. We developed a novel web and phone based PROs
tool for management of prostate cancer disease.METHODS: PRO methods for pros-
tate cancer were reviewed by analyzing published clinical studies. KOLs and pa-
tient advocacy groups were interviewed to obtain their input for design of PRO
disease management tool. Recent technologies for developing such tools were re-
viewed by analyzing available electronic PRO tools. PROCDIM design was devel-
oped based on secondary research and primary interviews. RESULTS: PROCDIM
was designed to capture patient reported outcomes data such as Quality of Life
(using five attributes), adverse events (six commonly reported AEs), medications
and OTC drugs history, PSA antigen score, past surgery and radiation therapy and
record of physician appointments. Patients could enter data into PROCDIM using
web or phone (iphone or andriod) based systems. Data from PROCDIM could be
emailed by patient to provider or could be downloaded by tethering phone to
computer. Pilot data was captured by testing PROCDIM with physicians and patient
advocacy groups. Based on interviews, PROCDIM was rated superior and highly
user friendly compared to current chronic disease management tools. Patient out-
comes data would be collected from a planned IRB approved study.CONCLUSIONS:
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